BROSSARD, Quebec, Sept. 05, 2018 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an agreement to provide a telemedicine platform based on CARA (Computer Assisted Retina Analysis) to Optina Diagnostics (“Optina”) for a period of 3 years. Optina will use DIAGNOS Cloud services to upload images generated by Optina’s hyperspectral camera for early detection of Alzheimer via key biomarkers in the retina of the eye.
The processed images will be available to be shared and further analysed by healthcare professionals and clinics in various locations. Optina will benefit from the high throughput of DIAGNOS CARA Cloud service as well as the ease of use of the teleophthalmology platform currently used by doctors and other medical professionals.
“At DIAGNOS, we are extremely happy to contribute to the success of innovative Quebec companies like Optina. Optina will leverage our experience and the high quality standard of CARA, a field proven platform approved for sale by the Food and Drug Administration in the United States, Health Canada and other countries’ homologation bodies. This partnership will foster more collaboration with other biotech firms and attract new clients in need of a telemedicine platform.” said Yves-Stephane Couture, Vice-President of sales at DIAGNOS.
“The partnership will greatly accelerate Optina’s commercialization of its Alzheimer diagnostic test, saving critical time to market while providing effective and efficient user experience.” said David Lapointe, President and CEO of Optina.